UK government to purchase 60 million doses of NVX-CoV2373 Novavax to partner with FUJIFILM Diosynth Biotechnologies to manufacture antigen component of NVX-CoV2373 in the UK Novavax and UK government to collaborate on Phase 3 clinical trial in UK commencing in the third quarter of this year...

SK bioscience to manufacture antigen component of NVX-CoV2373 Builds on and complements Novavax-CEPI collaboration to develop and distribute NVX-CoV2373 Novavax , SK bioscience and Republic of Korea intend to partner for manufacture and supply of vaccine for global markets including South Korea...

Announced Positive Phase 1 data of Phase 1/2 clinical trial of NVX-CoV2373 Secured $2 billion in funding for global coronavirus vaccine program through CEPI, DoD , and OWS Expanded large scale global manufacturing capacity through acquisition and partnering Company to host conference call today at...

Novavax will license COVID-19 vaccine technology to Takeda for local production and commercialization in Japan Matrix-M adjuvant to be supplied from Novavax Government of Japan will provide funding to Takeda for technology transfer, establishment of infrastructure and scale-up of manufacturing Adds...

Expected to support minimum of 1 billion doses of NVX-CoV2373 for India and low- and middle-income countries Leverages Serum Institute’s existing reach and infrastructure Builds on and complements Novavax-CEPI collaboration to develop and distribute NVX-CoV2373 for low- and middle-income countries...

GAITHERSBURG, Md. , Aug. 06, 2020 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq: NVAX), a late stage biotechnology company developing next-generation vaccines for serious infectious diseases, today announced it will report its second quarter 2020 financial and operating results following the close of...

Phase 1 portion of the Phase 1/2 clinical trial evaluated two doses of Novavax’ COVID-19 vaccine across two dose levels (5 and 25 µg) in 131 healthy adults ages 18-59 years NVX-CoV2373 was generally well-tolerated and had a reassuring safety profile The vaccine induced neutralization titers in 100%...

GAITHERSBURG, Md. and MORRISVILLE, N.C. , July 23, 2020 (GLOBE NEWSWIRE) -- Novavax, Inc. (NASDAQ: NVAX), a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, and FUJIFILM Diosynth Biotechnologies (FDB), a world leading contract development and...

GAITHERSBURG, Md. , July 20, 2020 (GLOBE NEWSWIRE) -- Novavax, Inc. (NASDAQ: NVAX), a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, today announced that Gregory M. Glenn , M.D., President of Research and Development, will present progress of...

Funding supports late-stage clinical development, including pivotal Phase 3 clinical trial to support licensure OWS award funds large-scale manufacturing of NVX-CoV2373, including production of 100 million doses starting in late 2020 GAITHERSBURG, Md....